{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:55:36Z","timestamp":1761540936135},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T00:00:00Z","timestamp":1247702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00417-009-1138-y","type":"journal-article","created":{"date-parts":[[2009,7,15]],"date-time":"2009-07-15T13:46:43Z","timestamp":1247665603000},"page":"1609-1616","source":"Crossref","is-referenced-by-count":23,"title":["Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study"],"prefix":"10.1007","volume":"247","author":[{"given":"Alexander","family":"Rouvas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Vergados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Pechtasides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Liarakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mitsopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ladas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,16]]},"reference":[{"key":"1138_CR1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0161-6420(95)30848-2","volume":"102","author":"The Central Vein Occlusion Study Group","year":"1995","unstructured":"The Central Vein Occlusion Study Group (1995) A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 102:1434\u20131444","journal-title":"Ophthalmology"},{"key":"1138_CR2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","volume":"102","author":"The Central Vein Occlusion Study Group","year":"1995","unstructured":"The Central Vein Occlusion Study Group (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 102:1425\u20131433","journal-title":"Ophthalmology"},{"key":"1138_CR3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1600-0420.2005.00592.x","volume":"83","author":"JB Jonas","year":"2005","unstructured":"Jonas JB (2005) Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 83:645\u2013663","journal-title":"Acta Ophthalmol Scand"},{"key":"1138_CR4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/112067210501500615","volume":"15","author":"JB Jonas","year":"2005","unstructured":"Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751\u2013758","journal-title":"Eur J Ophthalmol"},{"key":"1138_CR5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/01.iae.0000237111.82357.30","volume":"26","author":"NZ Gregori","year":"2006","unstructured":"Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, Smiddy WE, Murray TG, Berrocal AM, Scott IU, Gregori G (2006) One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 26:889\u2013895","journal-title":"Retina"},{"key":"1138_CR6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/01.iae.0000231543.45699.e1","volume":"26","author":"MJ Goff","year":"2006","unstructured":"Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR, Ai E (2006) Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 26:896\u2013901","journal-title":"Retina"},{"key":"1138_CR7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.eye.6702518","volume":"22","author":"PJ Patel","year":"2008","unstructured":"Patel PJ, Zaheer I, Karia N (2008) Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye 22:60\u201364","journal-title":"Eye"},{"key":"1138_CR8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-006-0348-9","volume":"24","author":"A Ramezani","year":"2006","unstructured":"Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S (2006) Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 24:1601\u20131606","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1138_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-006-9032-y","volume":"114","author":"MM Moschos","year":"2007","unstructured":"Moschos MM, Brouzas D, Loukianou E, Apostolopoulos M, Moschos M (2007) Intraocular triamcinolone acetonide for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 114:1\u20137","journal-title":"Doc Ophthalmol"},{"key":"1138_CR10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med 331:1480\u20131487","journal-title":"N Eng J Med"},{"key":"1138_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9394(14)72066-5","volume":"122","author":"RN Frank","year":"1996","unstructured":"Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW (1996) Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophrhalmol 122:393\u2013403","journal-title":"Am J Ophrhalmol"},{"key":"1138_CR12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","volume":"246","author":"PJ Keck","year":"1989","unstructured":"Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309\u20131312","journal-title":"Science"},{"key":"1138_CR13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306\u20131309","journal-title":"Science"},{"key":"1138_CR14","first-page":"1774","volume":"50","author":"DR Senger","year":"1990","unstructured":"Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774\u20131778","journal-title":"Cancer Res"},{"key":"1138_CR15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","volume":"142","author":"QD Nguyen","year":"2006","unstructured":"Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA (2006) Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961\u2013969","journal-title":"Am J Ophthalmol"},{"key":"1138_CR16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00006982-200603000-00005","volume":"26","author":"D Iturralde","year":"2006","unstructured":"Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279\u2013284","journal-title":"Retina"},{"key":"1138_CR17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00347-006-1355-2","volume":"103","author":"GB Jaissle","year":"2006","unstructured":"Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, V\u00f6lker M, Holz FG, Bartz-Schmidt KU (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103:471\u2013475","journal-title":"Ophthalmologe"},{"key":"1138_CR18","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00417-007-0569-6","volume":"245","author":"A Stahl","year":"2007","unstructured":"Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429\u20131436","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1138_CR19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/IAE.0b013e3180ed458d","volume":"27","author":"SG Priglinger","year":"2007","unstructured":"Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004\u20131012","journal-title":"Retina"},{"key":"1138_CR20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ajo.2007.07.038","volume":"14","author":"DC Ferrara","year":"2007","unstructured":"Ferrara DC, Koizumi H, Spaide RF (2007) Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 14:864\u2013871","journal-title":"Am J Ophthalmol"},{"key":"1138_CR21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/IAE.0b013e318050ca7c","volume":"27","author":"J Hsu","year":"2007","unstructured":"Hsu J, Kaiser RS, Sivalingam A, Abraham P, Fineman MS, Samuel MA, Vander JF, Regillo CD, Ho AC (2007) Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina 27:1013\u20131019","journal-title":"Retina"},{"key":"1138_CR22","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.ophtha.2008.06.021","volume":"115","author":"DJ Pieramici","year":"2008","unstructured":"Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL (2008) Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 115:e47\u2013e54","journal-title":"Ophthalmology"},{"key":"1138_CR23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR (2008) Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 16:791\u2013799","journal-title":"Mol Ther"},{"key":"1138_CR24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ajo.2008.08.016","volume":"147","author":"RF Spaide","year":"2009","unstructured":"Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R (2008). Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147:298\u2013306","journal-title":"Am J Ophthalmol"},{"key":"1138_CR25","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"1138_CR26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"issue":"8","key":"1138_CR27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/02713680802323140","volume":"33","author":"M El-Ashry","year":"2008","unstructured":"El-Ashry M, Hegde V, James P, Pagliarini S (2008) Analysis of macular thickness in British population using optical coherence tomography (OCT): an emphasis on interocular symmetry. Curr Eye Res 33(8):693\u2013699","journal-title":"Curr Eye Res"},{"key":"1138_CR28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2006.04.023","volume":"142","author":"BY Kim","year":"2006","unstructured":"Kim BY, Smith SD, Kaiser PK (2006) Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol 142:405\u2013412","journal-title":"Am J Ophthalmol"},{"key":"1138_CR29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","volume":"115","author":"The Central Vein Occlusion Study Group","year":"1997","unstructured":"The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115:486\u2013491","journal-title":"Arch Ophthalmol"},{"key":"1138_CR30","unstructured":"Food and Drug Administration (2006). www.fda.gov\/cder\/foi\/label\/2006\/125156lbl.pdf"},{"key":"1138_CR31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archopht.1993.01090080083022","volume":"111","author":"The Central Vein Occlusion Study Group","year":"1993","unstructured":"The Central Vein Occlusion Study Group (1993) Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol. 111:1087\u20131095","journal-title":"Arch Ophthalmol."}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-009-1138-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1138-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:48Z","timestamp":1559072448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-009-1138-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,16]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s00417-009-1138-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,16]]}}}